Loading clinical trials...

Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 Over 21 Days in Ambulatory Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease

NCT06482437•NMD Pharma A/S

View on ClinicalTrials.gov

Summary

This Phase 2a study aims to evaluate the efficacy, safety and tolerability of NMD670 vs placebo administered twice a day (BID) for 21 days in ambulatory adult patients with Charcot-Marie-Tooth disease type 1 and type 2.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female participants must be 18 to 70 years inclusive at the time of signing the ICF.
•Diagnosis of CMT type 1 or 2 confirmed by genetic testing.
•Body mass index between 18 and 35 kg/m2, inclusive, at screening, and with a minimum weight of 40 kg
•Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
•Participant is capable of and has given signed informed consent

Exclusion Criteria

•Participants with other significant disease that may interfere with the interpretation of study data (e.g., other neuromuscular diseases) and/or ability to complete the tests, in the opinion of the Investigator.
•Participants with laboratory test result abnormalities at screening considered clinically significant by the Investigator.
•Participants who have received treatment with another IMP within 30 days (or 5 half-lives of the medication, whichever is longer) prior to day 1.
•Participants with history of poor compliance with relevant therapy in the opinion of the Investigator.
•Female participants who plan to become pregnant during the study or are currently pregnant or breastfeeding.

Locations (19)

University of Kansas Medical Center, Department of Neurology

Kansas City, Kansas, United States

Mass General Neurology

Boston, Massachusetts, United States

NextGen Precision Health

Columbia, Missouri, United States

Columbia University Medical Center

New York, New York, United States

University of Rochester Neuromuscular Disease Center

Rochester, New York, United States

OSU Department of Neurology Division of Neuromuscular Diseases

Columbus, Ohio, United States

National Neuromuscular research Institute, PLLC

Austin, Texas, United States

Providence Medical Research Center

Spokane, Washington, United States

University Hospitals Leuven, Department of Neurology

Leuven, Belgium

CHR de la Citadelle- Site Citadelle Neurolgie Boulevard du 12eme de Ligne 1

Liège, Belgium

Key Dates

Start Date

September 30, 2024

Primary Completion Date

October 28, 2025

Completion Date

November 4, 2025

Last Updated

November 12, 2025

Enrollment

ACTUAL participants

Conditions

Charcot-Marie-Tooth Disease

Interventions

NMD670

DRUG

Placebo

DRUG

Longitudinal Biomarkers With Selected Outcome Measures In CMT

NCT06794489

CMT1ACMT (Charcot Marie Tooth Disease)+2 more

View study

RECRUITINGNA

Identification of Novel Biomarkers in Early Charcot-Marie-Tooth 1A Disease

NCT07049588

Charcot-Marie-Tooth Disease Type 1A

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 12, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease

Inclusion Criteria

Exclusion Criteria

Longitudinal Biomarkers With Selected Outcome Measures In CMT

Identification of Novel Biomarkers in Early Charcot-Marie-Tooth 1A Disease

High-Tech Rehabilitation Pathway for Chronic Adult Neuromuscular Diseases - Fit4MedRob-Chronic MND Project

Charcot-Marie-Tooth Disease (CMT) Biological Sample Collection for IPSC Generation and Biobanking

A Registered Cohort Study on Charcot-Marie-Tooth Disease

Evaluate the Safety and Potential Efficacy of Human Wharton's Jelly-derived Mesenchymal Stem Cells With Charcot-Marie-Tooth Disease Type 1E